公开(公告)号：US07485284B2

公开(公告)日：2009-02-03

申请号：US11341954

申请日：2006-01-27

申请人： Donald R. Vandevanter

发明人： Donald R. Vandevanter

IPC分类号： A61K49/00

CPC分类号： G01N33/5091 ,  G01N2333/31 ,  G01N2800/12 ,  G06F19/00 ,  G06Q50/24

摘要： Generally, the method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect comprises measuring a change in the status of lung infection in a sample population of subjects administered the agent in comparison to a control sample population of subjects; wherein the subjects in the sample population and the control sample population have the primary cystic fibrosis defect and are uninfected before the agent is administered; wherein a beneficial change in the presence of lung infection in the sample population in comparison to the control sample population is indicative of a treatment effect; and wherein the agent lacks intrinsic antibiotic activity.

摘要翻译： 通常，用于表征靶向原发性囊性纤维化缺陷的药剂的功效的方法包括测量与受试者的对照样品群体相比施用该试剂的受试者样本群体中肺部感染状态的变化; 其中样品群体中的受试者和对照样本群体具有原发性囊性纤维化缺陷，并且在施用该药剂之前未感染; 其中与对照样本群体相比，样品群体中肺部感染存在的有益变化指示治疗效果; 并且其中所述试剂缺乏内在的抗生素活性。